Skip to main content

News

News
09/20/2024
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY® Endovascular Robotic Surgical System has enrolled and completed follow-up for 50% of patients.
The ACCESS-PVI trial of LIBERTY®...
09/20/2024
IO Learning
News
09/04/2024
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the parallel #HOPE4LIVER trials, the novel ablation technique of histotripsy met coprimary end points for technical success and safety among patients with primary and metastatic liver tumors.
According to results from the...
09/04/2024
IO Learning
News
07/29/2024
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial, the addition of sorafenib to TACE improved survival outcomes and response among patients with recurrent intermediate-stage hepatocellular carcinoma after R0 initial hepatectomy and microvascular invasion.
According to a phase 3 trial,...
07/29/2024
Oncology
News
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
According to the phase 3...
07/18/2024
IO Learning
News
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients...
According to a post-hoc,...
07/17/2024
IO Learning
News
07/09/2024
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press Release Park City, Utah USA, July 9, 2024 – Transit Scientific, a Utah-based medical device company specializing in innovative solutions for vascular procedures, proudly announces the successful debut of XO...
Transit Scientific Press...
07/09/2024
Vascular Disease Management
Imaging Systems
05/08/2024

Siemens Healthineers and University Hospitals Cleveland News

Siemens Healthineers and University H...
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance cardiovascular services of the UH Harrington Heart & Vascular Institute with the world’s first clinically available photon-counting CT scanner and the new dual-source CT scanner.
The new alliance will enhance...
05/08/2024
Cath Lab Digest
News
04/25/2024
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual Meeting, first results from the #HOPE4LIVER trial evaluating histotripsy for primary and metastatic liver tumors were reported.
At the 2023 CIRSE Annual...
04/25/2024
IO Learning
News
04/24/2024

Syntervention Press Release

Syntervention Press Release
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina, USA, April 24, 2024 — Syntervention, Inc., a medical device company focused on meeting critical needs in the healthcare space, announces the impact of using its SWICKER® Radiopaque Surgical Foam Sponge in open...
Rocky Mount, North Carolina,...
04/24/2024
EP Lab Digest
News
11/30/2023
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx Medical today released information about their new ULTRA™ embolic platform designed to make therapeutic embolization procedures safer, better, and faster.   Embolization is a minimally invasive...
Salt Lake City (UT) – Fluidx...
11/30/2023
Vascular Disease Management